International Journal of Radiation Oncology*Biology*Physics10.1016/j.ijrobp.2003.09.0462004582344-352Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistanceHong Zhou, Yeon-Shil Kim, Aaron Peletier, Wes McCall, H.Shelton Earp, Carolyn I Sartor,
European Journal of Cancer Supplements10.1016/s1359-6349(06)70559-62006412168554 POSTER The mTOR effector p70 S6 kinase 1 (S6K1): a specific biomarker for the biological effects of the dual HER1/HER2 kinase inhibitor Lapatinib (GW572016) in HER2-overexpressing breast cancer cellsA. Vazquez-Martin, R. Colomer, J.A. Menendez,
Molecular Therapy10.1016/s1525-0016(16)35998-6201220S77194. Combining the Dual Tyrosine Kinase Inhibitor, Lapatinib, with HER2 Specific Cytotoxic T-Lymphocytes in the Treatment of HER2 Overexpressing Breast Cancer,
Cancer Chemotherapy and Pharmacology10.1007/s00280-007-0460-52007612179-188Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima®) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenograftsDaniel L. Gustafson, Barbara Frederick, Andrea L. Merz, David Raben,,
Breast Cancer Research10.1186/bcr-2001-72700200131Dual HER-2/EGFR tyrosine kinase inhibitorsFatima Cardoso,,
Breast Cancer Research10.1186/bcr54200023Tyrosine kinase signalling in breast cancer: Modulation of tyrosine kinase signalling in human breast cancer through altered expression of signalling intermediatesRania Kairouz, Roger J Daly,,
Clinical Breast Cancer10.1016/j.clbc.2016.05.0162016165344-348Neratinib, A Novel HER2-Targeted Tyrosine Kinase InhibitorShruti Rakesh Tiwari, Prasun Mishra, Jame Abraham,
Breast Cancer Research10.1186/bcr2280200911S1Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2+breast cancerH Cortés-Funes, C Mendiola, L Manso, E Ciruelos,,
European Journal of Cancer10.1016/s0959-8049(02)80848-6200238S62Antitumor activity of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (‘lressa’), alone or combined with gemcitabine and vinorelbine platinum-based chemotherapy, in human non-small-cell lung cancer (NSCLC) xenografts,
European Journal of Cancer Supplements10.1016/s1359-6349(06)70572-92006412172567 POSTER Efficacy of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in combination with cytotoxic agentsF. Solca, A. Baum, F. Himmelsbach, A. Amelsberg, G. Adolf,